Vertex
Life Sciences Radar, October 2026 edition. Evidence published up to 5 October 2026; job sites read on 6 October 2026. This brief covers AI in drug discovery, and research labs and data. Every link opens the public source.
Disclosure: Andrew Wyatt, Ortent's principal, was Chief Growth Officer at Sapio Sciences, a lab software company, until April 2026. He has no current relationship with, or financial interest in, Sapio or any other supplier. Software vendors, including Sapio and its competitors, appear in this brief only where public sources name them.
Status: Ortent has reviewed this brief; it has not been independently validated. It sets out what the company and others have published. Search coverage varies by company and is described under Coverage limits, and a count of zero means none was identified, not that nothing happened. It does not predict buying intent or measure operational maturity. For this radar, process and CMC development are grouped with manufacturing and excluded from research labs and data.
Scores
| Theme | Priority (1 to 10) | Delivery (0 to 10) | Stage | Commitments made public, last 12 months | R&D roles open on 6 Oct 2026 |
|---|---|---|---|---|---|
| AI in drug discovery | No eligible company disclosure identified | No eligible company disclosure identified | 0 | 8 | |
| Research labs and data | No eligible company disclosure identified | No eligible company disclosure identified | 0 | 4 |
The scores rest only on what the company itself has published about each theme. Commitments and open roles are observed activity: they show what is being started or staffed now, and they never change a score.
Summary
For Vertex, no eligible company disclosure was identified in either theme, so neither AI in drug discovery nor research labs and data has a score. No commitments in either theme were made public in the last 12 months or the year before. Its job postings point to existing work: an agentic AI co-scientist initiative, a Data and Computational Sciences organisation and a San Diego group that builds its own automated instruments for drug discovery. On 6 October 2026 Vertex had 8 R&D roles open in AI in drug discovery, including a Scientific Fellow leading the AI co-scientist work, and 4 in research labs and data, including a lab automation engineer whose posting asks for Hamilton and Biomek programming.
AI in drug discovery
No eligible company disclosure identified for this theme in the reviewed sources and period. This is not a finding that the company is inactive.
Commitments made public in the last 12 months: 0
None identified in the reviewed sources.
Commitments made public in the year before: 0
None identified in the reviewed sources.
Search coverage for this theme: partial. Commitments count once per initiative, however many announcements they get.
R&D roles open on 6 October 2026: 8
- Scientific Fellow, Agentic AI (AI Co-Scientist Lead), Boston, MA
- Senior Principal Scientist, Applied AI & Agentic Systems for Small-Molecule Drug Discovery, Boston, MA
- Senior Principal Scientist, Agentic Systems Development for Drug Discovery, Boston, MA
- Executive Director, Data & Methods (Data and Computational Sciences), Boston, MA
- Computational Chemistry Research Scientist (Computational Drug Design), Boston, MA
- Computational Chemistry Principal Research Scientist (Computational Drug Design), Boston, MA
- Computational Genomics Senior Research Scientist, San Diego, CA
- Computational Genomics Research Scientist, Boston, MA
These are postings listed on one day, not hires, headcount or a trend. Roles that serve both themes appear under each.
Technology named in these postings
Asked for as experience: Python, R.
A product named in a job advert shows what a team wants people to know. It is not proof of a purchase or an installed system.
Research labs and data
No eligible company disclosure identified for this theme in the reviewed sources and period. This is not a finding that the company is inactive.
Commitments made public in the last 12 months: 0
None identified in the reviewed sources.
Commitments made public in the year before: 0
None identified in the reviewed sources.
Search coverage for this theme: partial. Commitments count once per initiative, however many announcements they get.
R&D roles open on 6 October 2026: 4
- Lab Automation Engineer, Boston, MA
- Director, Cell & Gene Therapy Research Technology (Boston), Boston, MA
- High Throughput Biology Research Scientist, Boston, MA
- Optics / Microscopy Principal Scientist, San Diego, CA
These are postings listed on one day, not hires, headcount or a trend. Roles that serve both themes appear under each.
Technology named in these postings
Asked for as experience: Biomek, Hamilton, SQL, Benchling.
A product named in a job advert shows what a team wants people to know. It is not proof of a purchase or an installed system.
Two questions to investigate (Ortent's interpretation)
- Vertex's AI co-scientist lead is to weigh commercial, partner, open-source and in-house options and inform build, buy, partner or integrate decisions, while separate enterprise teams build an agentic AI platform. Who decides on adopting an external AI discovery tool, how is it funded and bought, and how does the research co-scientist work connect to the enterprise agent platform?
- A research technology director routes site needs to Laboratory Solutions or peer digital platform teams under a managed service model and holds the site budget, while a peer platform owner makes the build decision. Who owns lab platform and vendor decisions across research labs, and how do site budgets relate to platform buying?
Coverage limits
Vertex's investor site returned access errors, its newsroom failed to connect and the internet archive was unavailable, so results releases and presentations for the year before were not read and every search for that year is partial. Vertex hosts no call transcripts, and patents were not searched. Roles come from postings collected in an earlier search plus two added later; other open postings were scanned in bulk but not listed one by one. The absence of a score reflects what these searches found, not proof that Vertex has no activity in either theme.
Clarity when it counts.
For a board, advisory or fractional engagement, or a working call on the next stage, send a note. Thirty minutes is usually enough to test fit.
Request a 30-minute intro call